

Care-organization briefing

Micelle 60 | Version 1.2 | October 1, 2026

Sample material. This planning aid is not a released-product dossier, executed program agreement, CMS-approved implementation plan or individual medical advice. It uses synthetic Example reporting values. Micelle 60 remains a development-stage hemp-derived CBD isolate softgel; Medicare pays \$0 for the product.

Purpose and boundary

Use this briefing to compare organizational responsibilities with Micelle's available development records and determine which evidence is still needed. It does not establish laboratory results, product qualification, supply readiness or CMS eligibility.

What is available today

- **Review Room:** product, quality, implementation, patient material and dated readiness topics.
- **Development product sheet and specification structure:** planned 60 mg CBD per softgel and 60-softgel bottle; controlled fields Pending.
- **Quality Passport:** Example A, B and C interface records, not commercial lots or laboratory certificates.
- **Readiness register:** dated functional-owner actions and unresolved evidence.

For a structured 30-minute discussion, [request a briefing](#) or [email the care-organization team](#). Do not include patient information.

EXAMPLE

Requirement map

Topic	Organization responsibility	Micelle planning material
Governance	Assign clinical, quality, legal, privacy and operational decision rights.	Responsibility register and access framework.
Eligibility	Determine local criteria, exclusions, physician decision and documentation.	Sample planning structure only.
Shared decision	Record risks, benefits, preferences, medication review and follow-up.	Patient discussion guide.
Product qualification	Qualify finished product against approved specifications and genuine lot evidence.	Development sheet, source-status register and Example Passport.
Supply traceability	Control ordering, receipt, storage, lot and qualified-physician furnishing.	Example supply-log fields; no live supply.
Concerns and notices	Maintain escalation, emergency and lot-linked notice procedures.	Public concern route and planned lot notices.
Quarterly reports	Submit CMS-required reports and maintain source records.	Synthetic de-identified CSV; not a CMS submission.

Sample material. An organization must determine its own clinical, quality, legal, privacy and safety controls. Publication of planning material is not implementation or CMS approval.

Five stages, one accountable pathway

These stage names and responsibilities use the same canonical record as the website and access framework. All supply statements are conditional.

<p>01. Product review</p> <p>Organization: Evaluate the product definition, federal and state law, evidence and procurement suitability; keep the organization's own approval record.</p> <p>Micelle's planned support: Provide the development specification and source-linked Quality Passport examples, without claiming released-product compliance.</p>
<p>02. Organization implementation plan</p> <p>Organization: Elect the incentive if appropriate; prepare, submit and maintain a CMS-required plan covering product, eligibility, amount and frequency, safeguards, distribution and oversight. CMS approval belongs to CMS.</p> <p>Micelle's planned support: Offer an adaptable access framework and source-linked CMS crosswalk for the organization's review.</p>
<p>03. Shared decision-making</p> <p>Organization: An affiliated physician determines appropriateness, reviews medications and interactions, documents goals, preferences, risks and benefits, and plans follow-up.</p> <p>Micelle's planned support: Provide patient discussion materials, not an individual medical recommendation or eligibility decision.</p>
<p>04. Supply</p> <p>Organization: Arrange lawful procurement, inventory, storage and qualified-physician supply through the participant; do not direct beneficiaries to retail reimbursement.</p> <p>Micelle's planned support: If product is released, provide lot-labelled product and handling records under agreed arrangements; no supply service is live now.</p>
<p>05. Lot records and reporting</p> <p>Organization: Keep organization-controlled records and submit CMS-required quarterly reports; respond to requests and product notices. Do not place patient information in public examples.</p> <p>Micelle's planned support: Plan a public Quality Passport for each released lot and a checked de-identified export. The sample quarterly file is synthetic, not an actual CMS submission.</p>

Physician and patient materials

Material	Purpose	Status
Development product sheet	Planned label, pack, formulation and Pending specification fields.	Published development document
Controlled specification	Approved identity, assay, limits, method, effective date and source record.	Pending
Quality Passport	Lot identity, status, selected certificate, values and notice history.	Example records only
Patient discussion guide	Questions for a visit, medicines, goals and follow-up.	Versioned PDF available
Shared-decision record	Organization-controlled risks, preferences, medication review and follow-up.	Organization-specific
Concern route	Product concerns, emergency boundary and correspondence.	Public route; formal processing pending
Quarterly export	Organization reporting without patient identifiers in public examples.	Synthetic CSV only

Product distinction

Micelle 60 is a hemp-derived CBD isolate softgel in development. The separate NW PharmaTech 300 mg investigational product has no clinical, pharmacokinetic, exposure, efficacy, safety or comparability bridge to Micelle 60.

Sample quarterly record shape

Sample material. Every value and identifier below is illustrative. It does not represent actual supply, participants, testing, notices, performance or a CMS-approved report format.

Field	Example value
Reporting period	Example: 2027 Q1
Organization code	Example: ORG-DEMO-001
Prepared date	Example: 15 April 2027
Export version	Example: 1.0
Patient information	Not included

Example lot	Units	Recipients	Notices	Record status
EXAMPLE-A	Example: 120	Example: 72	Example: 0	Example released state
EXAMPLE-B	Example: 24	Example: 18	Example: 1	Example withdrawn state
EXAMPLE-C	Example: 60	Example: 41	Example: 0	Example corrected state

Exception and privacy fields

A real organization-controlled report would reconcile lot counts, certificates, notices, concerns, exceptions and document version. Do not include patient names, dates of birth, medical-record numbers, free-text clinical notes or other identifiers in shared public material. [Download the synthetic example CSV.](#)

Next steps and contact

A briefing can confirm the organization’s review questions, the responsible functions, the documents already available and the product evidence still required. It is not a clinical, legal, CMS or procurement sign-off.

Resource	Direct link
Development product sheet	Open the current product specification page
Quality Passport	View Example lot records
CMS crosswalk	Review source-linked model requirements
Care-organization pathway	Review the five-stage workflow
Status and readiness	Read dated evidence gaps and owner actions
Arrange a briefing	Open the direct email and telephone options

Email the care-organization team at team@nwpharmatech.com. Do not include patient information. Recheck online status before relying on this dated planning document.

EXAMPLE